Consensus CONMED Corporation

Stocks

CNMD

US2074101013

Medical Equipment, Supplies & Distribution

Market Closed - NYSE 16:00:02 2026-08-12 EDT			5-day change	1st Jan Change
49.48 ^USD	-0.20%		-1.83%	+21.87%

07-30	CONMED Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Raised	MT
07-30	CONMED Corporation, Q2 2026 Earnings Call, Jul 29, 2026

Evolution of the Average Target: CONMED Corporation

Evolution of the Target Price: CONMED Corporation

Changes in Analyst Recommendations: CONMED Corporation

7767b183ea8d5e8c1f090a8f6.OFbsC9XyNSJzLYJ7ewZZ_WfFkGuO0w8xBKYkRW24PgY.bTfeW4eeQ2kQaNE9H1IAlg-96h3kpEBHUt9LE1yNWGAAFYdn54NbRCB8ww~872548549853e04fca6c6a6a8cb281e7

Analysts' recommendations: CONMED Corporation

07-09	BMO Capital Initiates CONMED at Market Perform With $36 Price Target	MT
06-29	CONMED Lagging Medtech Peers as Growth Slows, BofA Securities Says	MT
06-29	BofA Downgrades CONMED to Underperform From Neutral, Keeps $40 Price Target	MT
05-18	BofA Securities Adjusts CONMED Price Target to $40 From $52	MT
03-17	Piper Sandler Downgrades CONMED to Neutral From Overweight, Adjusts PT to $39 From $55	MT
25-06-12	Conmed Shares Fall After Needham Downgrade	MT
25-06-12	Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target	MT
25-04-28	Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75	MT
25-02-06	JPMorgan Downgrades CONMED to Neutral From Overweight, Adjusts Price Target to $70 From $85	MT
24-08-01	Needham Adjusts CONMED's Price Target to $97 From $106, Keeps Buy Rating	MT
24-07-25	Needham Trims Price Target on CONMED to $106 From $107, Keeps Buy Rating	MT
24-04-25	Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating	MT
24-04-25	Needham Lowers Price Target on CONMED to $107 From $129, Notes Slight Guidance Cut Due to Currency, Keeps Buy Rating	MT
24-02-01	Needham Adjusts Price Target on CONMED to $129 From $119, Maintains Buy Rating	MT
24-02-01	JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating	MT
23-10-27	Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating	MT
23-10-26	Wells Fargo Cuts Price Target on CONMED to $107 From $123, Maintains Equalweight Rating	MT
23-07-27	Needham Adjusts Price Target on CONMED to $140 From $139, Maintains Buy Rating	MT
23-07-27	Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating	MT
23-06-05	Needham Raises Price Target on CONMED to $139 From $135, Keeps Buy Rating	MT
23-05-22	CL King Starts CONMED at Buy With $140 Price Target	MT
23-04-27	Piper Sandler Raises CONMED's Price Target to $128 From $118, Maintains Overweight Rating	MT
23-04-27	Wells Fargo Adjusts Price Target on CONMED to $119 From $96, Maintains Equal-Weight Rating	MT
23-04-27	Needham Adjusts Price Target on CONMED to $135 From $122, Reiterates Buy Rating	MT
23-04-27	Keybanc Adjusts Price Target on CONMED to $131 From $124, Maintains Overweight Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
CONMED CORPORATION	-	-8.23%
ABBOTT LABORATORIES		+7.93%
MEDTRONIC PLC		+8.56%
CENCORA, INC.		+11.6%
HOYA CORPORATION		+16.19%
BECTON, DICKINSON AND COMPANY		+5.84%
DEXCOM, INC.		+4.37%
MEDLINE INC.		+29.19%
WEST PHARMACEUTICAL SERVICES, INC.		+15.19%
TERUMO CORPORATION		+19.41%
Average		+11.00%
Weighted average by Cap.		+10.68%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

49.58USD

Average target price

45.50USD

Spread / Average Target

-8.23%

High Price Target

49.00USD

Spread / Highest target

-1.17%

Low Price Target

43.00USD

Spread / Lowest Target

-13.27%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BMO Capital
BofA Securities
Piper Sandler
Needham & Co.
Stifel Nicolaus
JPMorgan Chase
Wells Fargo Securities
KeyBanc Capital Markets
CL King
Jefferies & Co.
UBS
Barclays